Purine synthesis and salvage enzymes

Purine synthesis and salvage enzymes are a group of proteins responsible for the production and recycling of purine nucleotides, such as adenosine and guanosine, which are essential for DNA and RNA synthesis, energy transfer, and cell signaling (StatPearls, 2023). The de novo pathway builds these nucleotides from simple precursors like amino acids and carbon dioxide, while the salvage pathway recycles free bases like hypoxanthine and guanine, a process particularly important in tissues with limited de novo capacity like the brain (NCBI, 2022). Because rapidly proliferating cells, including cancer cells and activated immune cells, require high levels of purines, these enzymes are major therapeutic targets in oncology and rheumatology (Nature Reviews Cancer, 2019). Drugs such as methotrexate, 6-mercaptopurine, and mycophenolate mofetil work by inhibiting specific enzymes in these pathways, thereby depleting nucleotide pools and inducing cell cycle arrest or apoptosis (DrugBank, 2024). Additionally, genetic defects in these enzymes can lead to metabolic disorders such as gout and Lesch-Nyhan syndrome, making them targets for managing uric acid levels (NIH, 2023).

Other names

Purine metabolic pathway enzymesPurine nucleotide biosynthetic enzymesPurine salvage pathway proteins

Inhibition of key enzymes in the de novo and salvage pathways of purine nucleotide synthesis, resulting in the depletion of ATP and GTP pools and the subsequent disruption of DNA and RNA synthesis and repair.